The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AURA BIOSCIENCES INC | COM | 05153U107 | 28,210,198 | 3,039,892 | SH | SOLE | 1 | 3,039,892 | 0 | 0 | ||
CENTESSA PHARMACEUTICALS PLC | SPONSORED ADS | 152309100 | 76,858,154 | 19,963,157 | SH | SOLE | 1 | 19,963,157 | 0 | 0 | ||
PHATHOM PHARMACEUTICALS INC | COM | 71722W107 | 17,737,716 | 2,484,274 | SH | SOLE | 1 | 2,484,274 | 0 | 0 | ||
MERUS N V | COM | N5749R100 | 29,440,000 | 1,600,000 | SH | SOLE | 1 | 1,600,000 | 0 | 0 | ||
NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | N62509109 | 26,520,000 | 2,000,000 | SH | SOLE | 1 | 2,000,000 | 0 | 0 | ||
VAXCYTE INC | COM | 92243G108 | 54,619,604 | 1,457,300 | SH | SOLE | 1 | 1,457,300 | 0 | 0 |